GlassScriptPhysician profile
Sanjeev V Joshi
NPI 1962467563
$3,783.66
in general payments reported to CMS, 2019-2025
25 companies · $745 in 2025
The $745 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $198 · 2021: $289 · 2022: $540 · 2023: $380 · 2024: $751 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,876.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $601.72 | 2021-2025 | |
| Lilly USA, LLC | $582.03 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.65 | 2019-2022 | |
| Novo Nordisk INC | $337.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $304.43 | 2019-2024 | |
| Glaxosmithkline, LLC. | $213.83 | 2019-2023 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.04 | 2019-2024 | Xifaxan |
| Allergan, INC. | $130.59 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $128.17 | 2022-2025 | Farxiga, Breztri |
| Exact Sciences Corporation | $112.32 | 2023-2024 | Cologuard Collection Kit |
| Viiv Healthcare Company | $100.47 | 2024-2025 | Apretude |
| Radius Health, INC. | $96.39 | 2024-2025 | Tymlos |
| Intuitive Surgical, INC. | $89.42 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $80.89 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $77.63 | 2019-2025 | Veozah |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $62.45 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $60.93 | 2022-2024 | Spravato |
| Merck Sharp & Dohme LLC | $54.39 | 2022-2024 | Capvaxive, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $35.46 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $33.15 | 2021 | |
| Ardelyx, INC. | $27.13 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $25.62 | 2025 | Zenpep |
| Ars Pharmaceuticals Operations, INC. | $16.52 | 2025 | Neffy |
| Sumitomo Pharma America, INC. | $16.19 | 2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $13.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.